Monoclonal human Ab against sclerostin, ROMO, that targets the Wnt signaling pathway was recently approved as a new and potent anabolic agent for the treatment of women with postmenopausal osteoporosis at high risk of fracture. This evidence concerns the gene SOST and postmenopausal osteoporosis.